Belgium holds key position in European pharma sector, say pharma.be

25 October 2021

pharma.be, the umbrella organization of 125 innovative pharmaceutical companies active in Belgium, has published a brochure: "The Belgian biopharmaceutical sector, a pioneer in the competitive European biopharmaceutical landscape."

The latest figures illustrate the strong position of the Belgian pharmaceutical industry in Europe. This became even more evident during the health crisis we have been going through in recent months. Biopharmaceutical companies have made an unprecedented effort to find solutions to fight Covid-19 and have risen to the challenge of researching, manufacturing and distributing innovative patient solutions.

Belgian pharma in a few figures

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK